These findings suggest that small-molecule PDK4 inhibitors administrated orally could be utilized to develop a new class of neovascular AMD therapeutics, which might also be applicable for the therapy of other spectrums of neovascular diseases. This evidence concerns the gene PDK4 and age-related macular degeneration.